United States Biotechnology & Medical Research

Heron Therapeutics Inc (HRTX)

Track

The most recent insider trading activity for Heron Therapeutics Inc. occurred on August 8, 2025, involving significant buy transactions by Rubric Capital Management LP and Adam Morgan. These purchases represent the latest recorded activity, as no insider transactions have been reported within the last three months.
Ticker: HRTX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Heron Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 8 Aug 2025
Value US$1,359,174.48 | Price 27.99 | Shares 40,479 (+23.7%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-08-12 2025-08-08 B Purchase
3.6
Rubric Capital Management LP
Large shareholder
40,479 +23.7%
27.99
US$1,359,174 		40,479 +23.7% 27.99 US$1,359,174
2025-08-12 2025-08-08 B Purchase
1.9
Morgan Adam
Non-Executive Director
11,530 -26.8%
80.45
US$648,363 		11,530 -26.8% 80.45 US$648,363
2023-11-21 2023-11-17 B Purchase
3.5
Forbes William P

EVP, Chief Development Officer

Officer
37,754 +43.9%
274.47
US$3,797,479 		37,754 +43.9% 274.47 US$3,797,479
2023-11-20 2023-11-16 B Purchase
3.5
Forbes William P

EVP, Chief Development Officer

Officer
50,000 +1250.0%
0.94
US$46,995 		50,000 +1250.0% 0.94 US$46,995
2023-11-17 2023-11-16 B Purchase
3.7
Collard Craig A

Chief Executive Officer

Executive Director
150,000 +411.0%
0.92
US$137,970 		150,000 +411.0% 0.92 US$137,970
2023-11-17 2023-11-16 B Purchase
3.4
Duarte Ira

EVP, Chief Financial Officer

Officer
85,000 +inf%
0.89
US$75,599 		85,000 +inf% 0.89 US$75,599
2023-07-25 2023-07-21 B Purchase
1.9
Morgan Adam
Non-Executive Director
2,486,744 +55.3%
1.37
US$3,406,839 		2,486,744 +55.3% 1.37 US$3,406,839
2022-05-04 2022-05-03 PlS Planned sale
3.0
MANHARD KIMBERLY

EVP, Drug Development

Executive Director
1,504 -12.2%
4.76
US$7,154 		1,504 -12.2% 4.76 US$7,154
2021-12-23 2021-12-21 PlS Planned sale
Johnson Craig A
Non-Executive Director
250 -8.1%
9.73
US$2,432 		250 -8.1% 9.73 US$2,432
2021-12-23 2021-12-21 PlS Planned sale
2.5
Christian Waage
Non-Executive Director
300 -8.6%
9.73
US$2,920 		300 -8.6% 9.73 US$2,920
2021-06-22 2021-06-21 PlS Planned sale
2.5
Christian Waage
Non-Executive Director
300 -7.3%
15.20
US$4,559 		300 -7.3% 15.20 US$4,559
2021-06-22 2021-06-21 PlS Planned sale
Johnson Craig A
Non-Executive Director
250 -7.0%
15.20
US$3,801 		250 -7.0% 15.20 US$3,801
2021-04-16 2021-04-15 PlS Planned sale
2.5
Christian Waage
Non-Executive Director
300 -6.8%
17.51
US$5,254 		300 -6.8% 17.51 US$5,254
2021-04-07 2021-04-06 PlS Planned sale
Johnson Craig A
Non-Executive Director
250 -6.5%
17.22
US$4,305 		250 -6.5% 17.22 US$4,305
2021-01-15 2021-01-14 PlS Planned sale
Szekeres David Leslie

EVP, Chief Operating Officer

Officer
827 -100.0%
18.09
US$14,960 		827 -100.0% 18.09 US$14,960
2021-01-08 2021-01-08 PlS Planned sale
Szekeres David Leslie

EVP, Chief Operating Officer

Officer
3,571 -100.0%
19.66
US$70,219 		3,571 -100.0% 19.66 US$70,219
2020-12-23 2020-12-22 PlS Planned sale
3.0
MANHARD KIMBERLY

EVP, Drug Development

Executive Director
10,000 -100.0%
20.00
US$200,000 		10,000 -100.0% 20.00 US$200,000
2020-05-01 2020-05-01 PlS Planned sale
3.0
MANHARD KIMBERLY

Executive VP, Drug Development

Executive Director
1,158 -100.0%
13.97
US$16,176 		1,158 -100.0% 13.97 US$16,176
2019-12-03 2019-11-29 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Executive Director
24,000 -100.0%
26.00
US$624,000 		24,000 -100.0% 26.00 US$624,000
2019-10-07 2019-10-04 B Purchase
3.3
TANG KEVIN C
285,714 +5.2%
17.50
US$4,999,995 		285,714 +5.2% 17.50 US$4,999,995
2019-10-04 2019-10-03 B Purchase
2.5
Quart Barry D

Chief Executive Officer

Executive Director
4,571 +5.1%
17.50
US$79,992 		4,571 +5.1% 17.50 US$79,992
2019-10-04 2019-10-03 B Purchase
2.8
POYHONEN JOHN

EVP, Chief Commercial Officer

Executive Director
5,143 +39.6%
17.50
US$90,002 		5,143 +39.6% 17.50 US$90,002
2019-05-23 2019-05-22 B Purchase
2.8
POYHONEN JOHN
Non-Executive Director
3,000 +30.0%
17.55
US$52,650 		3,000 +30.0% 17.55 US$52,650
2019-05-16 2019-05-15 B Purchase
2.5
Christian Waage
1,400 +inf%
18.04
US$25,262 		1,400 +inf% 18.04 US$25,262
2019-05-02 2019-05-01 PlS Planned sale
3.0
MANHARD KIMBERLY

Executive VP, Drug Development

Officer
1,109 -100.0%
18.86
US$20,918 		1,109 -100.0% 18.86 US$20,918
2018-11-02 2018-11-02 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
494 -100.0%
30.62
US$15,125 		494 -100.0% 30.62 US$15,125
2018-10-02 2018-10-01 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
6,000 -100.0%
32.07
US$192,433 		6,000 -100.0% 32.07 US$192,433
2018-09-12 2018-09-12 S Sale TANG KEVIN C Non-Executive Director Large shareholder
2,695,000 -31.6%
35.75
US$96,346,250 		2,695,000 -31.6% 35.75 US$96,346,250
2018-07-03 2018-07-02 PlS Planned sale Rosen Robert

President

Executive Director
3,400 -56.3%
38.75
US$131,765 		3,400 -56.3% 38.75 US$131,765
2018-07-03 2018-07-02 PlS Planned sale Rosen Robert

President

Executive Director
92,131 -93.8%
38.13
US$3,512,918 		92,131 -93.8% 38.13 US$3,512,918
2018-07-03 2018-07-02 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
100 -100.0%
38.85
US$3,885 		100 -100.0% 38.85 US$3,885
2018-07-03 2018-07-02 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
5,900 -98.3%
37.51
US$221,294 		5,900 -98.3% 37.51 US$221,294
2018-07-03 2018-07-02 PlS Planned sale HOFFMAN ROBERT

CFO & SVP, Finance

Officer
1,060 -45.3%
38.80
US$41,123 		1,060 -45.3% 38.80 US$41,123
2018-07-03 2018-07-02 PlS Planned sale HOFFMAN ROBERT

CFO & SVP, Finance

Officer
28,940 -92.5%
38.15
US$1,104,107 		28,940 -92.5% 38.15 US$1,104,107
2018-07-03 2018-06-29 PlS Planned sale Rosen Robert

President

Executive Director
2,112 -44.4%
41.39
US$87,415 		2,112 -44.4% 41.39 US$87,415
2018-07-03 2018-06-29 PlS Planned sale Rosen Robert

President

Executive Director
51,696 -91.6%
40.17
US$2,076,597 		51,696 -91.6% 40.17 US$2,076,597
2018-07-03 2018-06-29 PlS Planned sale Rosen Robert

President

Executive Director
75,661 -57.3%
39.14
US$2,961,122 		75,661 -57.3% 39.14 US$2,961,122
2018-06-22 2018-06-21 PlS Planned sale Quart Barry D

Chief Executive Officer

Executive Director
50,000 -41.8%
39.05
US$1,952,500 		50,000 -41.8% 39.05 US$1,952,500
2018-04-02 2018-03-29 B Purchase TANG KEVIN C Large shareholder
192,308 +2.3%
26.00
US$5,000,008 		192,308 +2.3% 26.00 US$5,000,008
2018-03-19 2018-03-19 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development
18,000 -100.0%
30.00
US$540,000 		18,000 -100.0% 30.00 US$540,000
2018-03-19 2018-03-19 PlS Planned sale Quart Barry D

Chief Executive Officer

Executive Director
100,000 -59.5%
29.75
US$2,975,000 		100,000 -59.5% 29.75 US$2,975,000
2018-03-16 2018-03-14 PlS Planned sale Quart Barry D

Chief Executive Officer

Executive Director
100,000 -59.5%
24.75
US$2,475,000 		100,000 -59.5% 24.75 US$2,475,000
2018-01-12 2018-01-10 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
7,584 -100.0%
20.00
US$151,680 		7,584 -100.0% 20.00 US$151,680
2017-04-24 2017-04-24 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development
21,542 -100.0%
15.33
US$330,263 		21,542 -100.0% 15.33 US$330,263
2017-01-23 2017-01-19 B Purchase POYHONEN JOHN
10,000 +inf%
12.20
US$122,000 		10,000 +inf% 12.20 US$122,000
2017-01-23 2017-01-19 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
2,459,016 +41.9%
12.20
US$29,999,995 		2,459,016 +41.9% 12.20 US$29,999,995
2016-08-12 2016-08-10 PlS Planned sale Rosen Robert

President & CCO

Executive Director
12,400 -82.4%
23.89
US$296,278 		12,400 -82.4% 23.89 US$296,278
2016-08-12 2016-08-10 PlS Planned sale Rosen Robert

President & CCO

Executive Director
87,600 -85.3%
23.21
US$2,033,616 		87,600 -85.3% 23.21 US$2,033,616
2016-04-21 2016-04-21 PlS Planned sale Rosen Robert

President

Executive Director
19,662 -88.2%
22.15
US$435,433 		19,662 -88.2% 22.15 US$435,433
2016-04-21 2016-04-20 PlS Planned sale Rosen Robert

President

Executive Director
4,010 -60.3%
22.19
US$88,967 		4,010 -60.3% 22.19 US$88,967
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
6,230 -70.2%
25.11
US$156,438 		6,230 -70.2% 25.11 US$156,438
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
32,224 -78.4%
24.49
US$789,037 		32,224 -78.4% 24.49 US$789,037
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
76,949 -65.2%
23.47
US$1,805,955 		76,949 -65.2% 23.47 US$1,805,955
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
60,925 -34.0%
22.50
US$1,370,593 		60,925 -34.0% 22.50 US$1,370,593
2015-06-12 2015-06-10 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
121,212 +2.6%
24.75
US$2,999,997 		121,212 +2.6% 24.75 US$2,999,997
2015-06-03 2015-06-02 S Sale MANHARD KIMBERLY Non-Executive Director
10,500 -100.0%
23.58
US$247,590 		10,500 -100.0% 23.58 US$247,590
2015-06-02 2015-06-02 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
32,395 +0.7%
23.84
US$772,294 		32,395 +0.7% 23.84 US$772,294
2015-06-03 2015-06-01 S Sale MANHARD KIMBERLY Non-Executive Director
2,708 -100.0%
21.17
US$57,328 		2,708 -100.0% 21.17 US$57,328
2015-06-02 2015-06-01 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
2,380 +0.1%
19.30
US$45,934 		2,380 +0.1% 19.30 US$45,934
2015-06-02 2015-05-29 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
115,225 +2.5%
19.74
US$2,274,058 		115,225 +2.5% 19.74 US$2,274,058
2015-03-09 2015-03-05 PlS Planned sale Marshall Paul

SVP, Technical Operations

Officer
20,000 -100.0%
15.40
US$308,000 		20,000 -100.0% 15.40 US$308,000
2015-03-09 2015-03-05 PlS Planned sale Marshall Paul

SVP, Technical Operations

Officer
50,000 -71.4%
14.40
US$720,000 		50,000 -71.4% 14.40 US$720,000
2014-06-27 2014-06-25 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
510,638 +12.5%
11.75
US$5,999,996 		510,638 +12.5% 11.75 US$5,999,996
2014-06-26 2014-06-25 B Purchase Quart Barry D

Chief Executive Officer

Executive Director
10,000 +19.3%
11.75
US$117,500 		10,000 +19.3% 11.75 US$117,500
2013-11-21 2013-11-20 B Purchase Quart Barry D

Chief Executive Officer

Executive Director
1,000,000 +2695.4%
0.40
US$400,000 		1,000,000 +2695.4% 0.40 US$400,000
2012-09-12 2012-07-25 B Purchase SPCH, LLLP Large shareholder
38,095,238 +inf%
0.53
US$20,000,000 		38,095,238 +inf% 0.53 US$20,000,000
2009-10-21 2009-10-19 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
2,443,181 +30.6%
0.88
US$2,149,999 		2,443,181 +30.6% 0.88 US$2,149,999
2009-01-05 2008-12-31 B Purchase TANG KEVIN C Large shareholder
175,000 +2.2%
0.42
US$72,625 		175,000 +2.2% 0.42 US$72,625
2008-12-22 2008-12-18 B Purchase TANG KEVIN C Large shareholder
415,300 +5.6%
0.48
US$200,673 		415,300 +5.6% 0.48 US$200,673
2008-11-17 2008-11-13 B Purchase TANG KEVIN C Large shareholder
775,032 +11.7%
0.48
US$372,015 		775,032 +11.7% 0.48 US$372,015
2008-11-17 2008-11-13 B Purchase TANG KEVIN C Large shareholder
66,000 +1.0%
0.50
US$32,710 		66,000 +1.0% 0.50 US$32,710
2008-11-12 2008-11-10 S Sale ROSENBLATT TOBY Non-Executive Director
40,000 -100.0%
0.51
US$20,524 		40,000 -100.0% 0.51 US$20,524
2008-11-12 2008-11-10 S Sale ROSENBLATT TOBY Non-Executive Director
6,881 -18.5%
0.51
US$3,531 		6,881 -18.5% 0.51 US$3,531
2008-11-04 2008-10-31 B Purchase TANG KEVIN C Large shareholder
336,300 +5.4%
0.61
US$204,067 		336,300 +5.4% 0.61 US$204,067
2008-10-14 2008-10-10 B Purchase TANG KEVIN C Large shareholder
870,000 +16.2%
0.74
US$647,019 		870,000 +16.2% 0.74 US$647,019
Explore more

More insider trading research around Heron Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America